Summary Epidermal growth factor receptor (EGFR) was studied in ovarian tumours with immunohistochemical (IH) and ligand-binding assay (LBA). Two different monoclonal antibodies (MoAbs: 2E9, EGFR1) with respect to detecting EGFR with different ligand-binding affinities (low, high and low) were used. When comparing the IH data of MoAbs 2E9 and EGFR1 a significant correlation was found (2P<0.0001). Both antibodies stained 77% of the adenocarcinoma samples. Evidence is increasing that growth factors and their receptors are involved not only in control of normal cell growth, but also in diseases, including cancer. The epidermal growth factor (EGF) and its receptor (EGFR) in particular have been investigated extensively in several tumour types. The EGFR molecule comprises a 170 kDa membrane protein, exhibiting an extracellular ligand (EGF or TGF-a) binding domain, a trans-membrane region and an intracellular domain facing the cytoplasm and exhibiting tyrosine kinase function. In many cell types the external domain displays high affinity (minor class) and low affinity (major class) EGF binding sites. The high-affinity binding sites prove to be most important for the activation of the signal transducing cascade (Defize et al., 1989) . Both EGF and EGFR play an essential role in the development of mammary tissue (Tailor-Papadimitriou et al., 1977). Overexpression of EGFR in human primary breast cancer has been shown to be an indicator of a bad prognosis with respect to both relapse-free and overall survival (Sainsbury et al., 1987) and response to hormonal therapy of advanced disease (Nicholson et al., 1989) . However, no consensus exists regarding the prognostic significance of EGFR . With respect to the ovary, changes in the level of EGF and EGFR in normal and neoplastic (benign/malignant) ovarian tissue specimens and its relation to clinical outcome have been studied less extensively (Bauknecht et al., , 1989 (Bauknecht et al., , 1990 Berchuck et al., 1991; Owens et al., 1991). In the present study we have investigated EGFR status in ovarian tissues with immunohistochemical (IH) and biochemical techniques (LBA: ligand binding assay). The IH technique was chosen for comparison with LBA because of its ability to identify tumour positivity at the cellular level, even in small tumour samples, excluding the influence of variance of tumour cellularity and the presence of EGFR in non-tumour tissue. Moreover, two different monoclonal antibodies (MoAbs: 2E9, EGFR1) were used to study possible differences in staining pattern between monoclonal antibodies reactive to different subtypes of receptor with respect to its ligand binding affinity. 
Evidence is increasing that growth factors and their receptors are involved not only in control of normal cell growth, but also in diseases, including cancer. The epidermal growth factor (EGF) and its receptor (EGFR) in particular have been investigated extensively in several tumour types. The EGFR molecule comprises a 170 kDa membrane protein, exhibiting an extracellular ligand (EGF or TGF-a) binding domain, a trans-membrane region and an intracellular domain facing the cytoplasm and exhibiting tyrosine kinase function. In many cell types the external domain displays high affinity (minor class) and low affinity (major class) EGF binding sites. The high-affinity binding sites prove to be most important for the activation of the signal transducing cascade (Defize et al., 1989) . Both EGF and EGFR play an essential role in the development of mammary tissue (Tailor-Papadimitriou et al., 1977) . Overexpression of EGFR in human primary breast cancer has been shown to be an indicator of a bad prognosis with respect to both relapse-free and overall survival (Sainsbury et al., 1987) and response to hormonal therapy of advanced disease (Nicholson et al., 1989) . However, no consensus exists regarding the prognostic significance of EGFR . With respect to the ovary, changes in the level of EGF and EGFR in normal and neoplastic (benign/malignant) ovarian tissue specimens and its relation to clinical outcome have been studied less extensively (Bauknecht et al., , 1989 (Bauknecht et al., , 1990 Berchuck et al., 1991; Owens et al., 1991) . In the present study we have investigated EGFR status in ovarian tissues with immunohistochemical (IH) and biochemical techniques (LBA: ligand binding assay). The IH technique was chosen for comparison with LBA because of its ability to identify tumour positivity at the cellular level, even in small tumour samples, excluding the influence of variance of tumour cellularity and the presence of EGFR in non-tumour tissue. Moreover, two different monoclonal antibodies (MoAbs: 2E9, EGFR1) were used to study possible differences in staining pattern between monoclonal antibodies reactive to different subtypes of receptor with respect to its ligand binding affinity. 
Materials and methods

Patients
One-hundred and twenty-eight tumours (121 epithelial and 7 non-epithelial), and 21 non-tumorous ovaries were analysed.
Tumours were classifed in accordance with WHO classification (Serov et al., 1973 Group, 1980) . The homogenate was centrifuged for 30 min at 100,000 g at 4°C, and the pellet fraction obtained was rehomogenised in 2.5 ml of buffer A (20 mM phosphate buffer pH 7.4, containing 0.15 M NaCl and 70 jLg ml-' Bacitracin) in an ice-bath with three 5-s bursts at 20,000 r.p.m. of an Omni-1000 tissue homogeniser (OMNI International, Waterbury, CT, USA). The homogenate was centrifuged for 10min at 1000g, and the supernatant was defined as membrane preparation. After taking an aliquot for membrane-protein determination, 1.1% (w/v) bovine serum albumin (BSA, purified Behringwerke AG, Marburg, Germany) in buffer A was added to a final concentration of 0.1% (w/v) BSA. Cell membrane preparation aliquots of 100 jlL were incubated with eight concentrations (ranging from 0.15 to 3.5 nM) of '25I-mEGF (mouse-EGF, receptor grade; Bioproducts for science, Inc., Indianapolis, IN, USA) tracer in a final volume of 140 jil for 16 h at 20'C.
Non-specific binding was assessed in duplicate using 0.75 nM '25I-mEGF and a 250-fold excess of non-labelled mEGF. lodinated mEGF (specific activity 500-600 Ci mmol 1), prepared with Protag-125 or Enzymobeads (as described in detail by Kienhuis et al., 1991) , was kindly provided by Dr Th.J. Benraad (Sint Radboud Hospital, Nijmegen, The Netherlands). Separation of bound and free ligand was achieved using hydrosylapatite (essentially as described by Benraad & Foekens, 1990) after minor modifications (Koenders et al., 1991) . Receptor values were calculated by Scatchard analysis and expressed as fmol/mg of membrane protein.
A membrane protein threshold of 0.2 mg ml ' was adopted to avoid possible false-negative results (Koenders et al., 1991) .
Gene amplification
For studying EGFR gene copy numbers, DNA isolated from an aliquot of the total tissue homogenate of 25 ovarian carcinomas was digested with either Eco RI or Hind III, size fractioned on a 1% agarose gel and transferred to a nylon membrane Hybond N+ (Amersham, Buckinghamshire, UK) (Davis et al., 1986) . The EGFR probe was labelled by random primer extension (Feinberg & Vogelstein, 1983 ) using 32p-dATP. The filters were hybridised overnight at 65°C.
Filters were washed at high stringency (0.3 x SSC at 65C) and autoradiographed using Kodak XAR-5 film for 1 or 5 days at -70°C, as described before . Autoradiographs were scanned with a Bio-Rad Video densitometer 620. The IGF-1-receptor probe (pIGF-9-R.8, ATCC 59295) was used as a control (two gene copies) for densitometry and for the amount of DNA loaded on the gel. Figure Id) . If a tumour was considered positive when one epithelial cell stained with one of the MoAbs, no significant difference was found in the incidence of positivity between the adenocarcinomas (primary tumours or metastases) and the other 21 benign epithelial tumours (77% vs 70% positive for MoAb-2E9, and 76% vs 77% for MoAb-EGFR1, respectively) (Table I) . However, apart from one MTI tissue with MoAb-EGFRl, the maximal intensity score (i max; Figure Id , e) with MoAb-2E9 and/or MoAb-EGFRl was only observed for a varying number of cells (5-80%) in ± 12.5% of the adenocarcinoma tissues (primary tumours-+ metastases) examined (Table I ). In 6 of these 13 tumour samples with a maximal staining intensity examined, as well as in 19 other adenocarcinomas, no amplification or rearrangement of the EGFR-gene was found by Southern blot analysis. The incidence of positivity with both MoAbs was not clearly different among the histological subtypes of the adenocarcinomas (Table II) .
In the total group of adenocarcinomas, both MoAbs gave similar incidences of positivity, i.e. 75% positive for primary tumours with both MoAbs, and 86% with MoAb-2E9 and 85% with MoAb-EGFRI for metastatic tumour samples respectively (Table I ). Parallel to an increased percentage of incidence of positivity, the median level of the percentage of stained cells was higher in the metastatic lesions as compared with the primary tumours (for MoAb-2E9: 76% vs 36%, 2P<0.05; for MoAb-EGFRl: 67% vs 45%, 2P= 0.08) ( Table I) . A similar trend was found for specimens of the primary tumours and metastatic lesions of six patients from whom both biopsies were obtained (Table III) .
Regarding 3/3 (100) 100 0 ai-max: number of patients with maximal staining intensity (grade 3). Mann-Whitney U-test: 2P < 0.05b and 2P =0.08c. accordance between data obtained with LBA and MoAb-EGFR1 was highest (only 28% discordance). There was no significant difference in the percentage of stained cells with MoAb-2E9 in tumours positive or negative for EGFR as assessed by LBA (Figure 2, left Battaglia et al. (1989) , but these findings were not confirmed by others (Bauknecht et al., 1990; Berchuck et al., 1991) . No significant difference was observed in the incidence of EGFRpositivity among the histological subtypes of adenocarcinomas (Table II) , as was also suggested before by Witmaack et al. (1988) . In general, the staining was cytoplasmic for both MoAbs, as has also been reported by others (Damjanov et al., 1986; Defize et al., 1986; Rodriquez et al., 1991; Berchuck et al., 1991 (Defize et al., 1989) .
The 28% discordances observed between LBA and MoAb-EGFR1 may not just be caused by heterogeneity in tissue distribution of EGFR but also by the presence of EGFR- positive stromal-derived membranes, causing EGFR-positivity in LBA and EGFR-negativity with IH using MoAb-EGFRl when scoring only epithelial cells. This latter possibility is not likely, as the stromal compartment of tumours which scored positive in LBA and, negative with IH was negative for EGFR with MoAb-EGFRl. Some of the discordances may have been caused by the presence of receptors with an intact antigenic site, scoring positive with IH but negative with LBA, as they are unable to bind ligand. However, to our knowledge no such receptors unable to bind ligand have been described in the literature for any tumour tissue. It is important to keep in mind that with LBA only EGFR localised in the crude membrane preparation was determined and that with IH cytoplasmic staining was most frequently observed in all specimens. Thus the two techniques detect receptors at entirely different subcellular localisations, and it may therefore be unrealistic to expect full concordances between LBA and IH.
In summary, although highly significant correlations were found between the levels of EGFR measured by LBA as compared with the percentage of positive tumour cells stained immunohistochemically with MoAb-EGFRI, at least in part different EGFR entities are probably determined by both techniques. Clinical studies with the lengths of relapsefree and overall survival as parameters are necessary to establish the possible prognostic impact of EGFR determined with either methodology or whether a combination of both will give a better discrimination of high-and low-risk patients. Such a study is currently in progress.
